Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Stopped The study closed to enrollment prior to fully accruing due to difficulties with slower than expected accrual.

Conditions

• Respiratory Syncytial Virus (RSV)

Interventions

• BIOLOGICAL: RSV ΔNS2/Δ1313/I1314L Vaccine
• BIOLOGICAL: RSV 6120/ΔNS2/1030s Vaccine
• BIOLOGICAL: RSV 276 Vaccine
• BIOLOGICAL: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)